New study aims to spot hidden liver disease before standard tests show trouble.
NCT ID NCT07205874
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looks for early signs of primary biliary cholangitis (PBC) in adults who have certain antibodies (AMA) but normal liver enzyme levels (ALP). Researchers will perform liver biopsies and special blood tests on 80 participants to find clues that could lead to earlier diagnosis. The goal is to catch the disease sooner, when treatment might be more effective.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could help doctors diagnose PBC earlier, before standard blood tests show signs of liver damage.
- What could go wrong
- This is a small, early observational study. It may not find reliable predictive factors, and results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY BILIARY CHOLANGITIS (PBC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hospital Universitario La Paz
RECRUITINGMadrid, 28046, Spain
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a common cholesterol drug help manage a rare liver disease?
- One pill may tame both itchy skin and stubborn liver disease
- Can a smartwatch help manage a rare liver disease? stanford study investigates
- Can breathing and meditation ease PBC symptoms? new study says maybe.
- New hope for PBC: experimental drug CS0159 enters Mid-Stage trial
- 3000-Patient study aims to predict PBC outcomes from blood tests